Crescent Biopharma, Inc. (CBIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
300 Fifth Avenue
Waltham, MA 02451
United States of America (the)
Phone
617-430-5595
Sector
Healthcare
Industry
Biotechnology
Employees
41
First IPO Date
January 10, 2014
| Name | Title | Pay | Year Born |
| Joshua T. Brumm | Chief Executive Officer & Director | 1.25M | 1978 |
| Ellie Im | Chief Medical Officer | 847,841 | 1978 |
| Jonathan McNeill | President & Chief Operating Officer | 871,682 | 1985 |
| Wenjie Cheng | Senior Vice President of Technical Operations | 0 | N/A |
| Christopher Doughty | Chief Business Officer | 0 | 1988 |
| Richard William Scalzo | Chief Financial Officer | 0 | 1986 |
| Ryan Lynch | Senior Vice President of Finance, Treasurer & Chief Accounting Officer | 0 | 1984 |
| Barbara H. Bispham | General Counsel & Corporate Secretary | 0 | 1987 |
| Amy Reilly | Chief Communications Officer | 0 | 1974 |
| Jan Pinkas | Chief Scientific Officer | 0 | 1969 |
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.